TG Therapeutics, Inc. (TGTX) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. TG Therapeutics is a commercial-stage biopharmaceutical company focused on B-cell diseases. Its primary marketed product is BRIUMVI (ublituximab-xiiy), approved for relapsing forms of multiple sclerosis (RMS) in the U.S., EU, and UK. The company is also advancing azer-cel (azercabtagene zapreleucel) for autoimmune indications following a license agreement with Precision BioSciences.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $83,879 | $165,815 | $220,819 | $189,691 |
| Product Revenue (Net) | $83,297 | $25,068 | $206,381 | $48,868 |
| License/Milestone Revenue | $582 | $140,747 | $14,438 | $140,823 |
| Net Income | $3,880 | $113,930 | $52 | $27,088 |
| Operating Income | $12,434 | $114,784 | $11,980 | $33,118 |
| Cash & Equivalents | $195,822 | $92,933 | As of Sept 30, 2024 | |
| Total Debt (Non-Current) | $244,158 | $100,118 | As of Sept 30, 2024 |
Note: Q3 2023 revenue included a one-time $140 million upfront payment from a commercialization agreement. Q3 2024 product revenue grew 232% year-over-year.
Material Changes vs. Prior Period
- Revenue Composition: Total revenue decreased significantly in Q3 2024 compared to Q3 2023 due to the absence of the $140 million non-refundable upfront license payment recognized in the prior year. However, net product revenue from BRIUMVI sales surged from $25.1 million to $83.3 million.
- Debt Refinancing: In August 2024, the company entered a new $250 million term loan with Blue Owl Capital, refinancing its prior debt with Hercules Capital. This resulted in a $4.6 million loss on extinguishment of debt recorded in Q3 2024.
- Expense Growth: Selling, general, and administrative (SG&A) expenses increased to $42.0 million in Q3 2024 from $32.8 million in Q3 2023, driven by commercialization costs and higher noncash stock compensation ($8.7 million vs. $6.3 million).
- Inventory Buildup: Inventory increased to $84.7 million from $39.8 million at year-end 2023 to support forecasted sales and supply commitments to partners.
Guidance, Outlook, and Risks
- Outlook: Management believes existing cash, investments ($341 million total), and projected BRIUMVI revenues are sufficient to fund operations for at least 12 months. The company expects gross margins to decrease modestly after Q1 2025 as pre-commercialization inventory is depleted.
- Share Repurchase: The Board authorized a $100 million share repurchase program in August 2024. As of September 30, 2024, the company repurchased 92,301 shares for approximately $2.1 million.
- Material Weakness: The company identified a material weakness in internal controls over financial reporting related to non-routine share-based payment awards. Management is implementing remediation plans expected to be complete by December 31, 2024.
- Risks: Key risks include the ability to maintain regulatory approval for BRIUMVI, competition in the RMS market, reliance on third-party manufacturers (Samsung Biologics), and the success of the ex-U.S. commercialization partner (Neuraxpharm).
Investor Verification Checklist
- Debt Covenants: Verify compliance with the new Blue Owl financing agreement covenants, specifically regarding US Net Sales thresholds and leverage ratios.
- Inventory Valuation: Monitor inventory levels ($84.7 million) and potential write-downs as the company transitions from pre-commercial to commercial manufacturing costs.
- Internal Controls: Track the remediation progress of the identified material weakness in share-based compensation accounting.
- Partner Performance: Assess Neuraxpharm's commercialization progress in the EU and UK, as future milestone payments and royalties depend on their success.
- Cash Burn: Review operating cash flow trends, noting the shift from net income to cash usage in operating activities due to working capital changes (inventory and receivables).